First-in-class science
The only Treg-activating monoclonal antibody.
Investors & Partners
A high-impact opportunity
CD4 Therapeutics offers a de-risked investment in next-generation immunotherapy with clear market leadership potential. The full investment case is shared on request, not as a public download.
The case
Why invest in CD4?
€10B+ market potential
Autoimmune and oncology focus.
De-risked clinical strategy
Proven proof-of-concept, targeted success.
Fast-track regulatory pathways
U.S. Orphan Drug Designation granted for aGvHD.
Clear exit strategies
Licensing, M&A, IPO.
Key figures
The numbers behind the case
€10B+
combined lead opportunity across oLP and aGvHD
€20B+
total market with expansion into RA, AD and IBD
80+
years of combined team experience
6
programs, led by an EIC Accelerator-funded Phase 2b
The deal
Worldwide exclusive licence
In July 2024, T-Balance Therapeutics GmbH and CD4 Therapeutics GmbH, a biotech company based in the Munich area, signed an exclusive binding term sheet granting CD4 Therapeutics worldwide rights to develop and commercialize Tregalizumab.
July 2024
Exclusive binding term sheet
T-Balance Therapeutics GmbH grants CD4 Therapeutics worldwide rights to develop and commercialize Tregalizumab.
Company
Munich area, Germany
CD4 Therapeutics GmbH, Kiefernweg 38, 82319 Starnberg. Amtsgericht München HRB 295471.
Strategic options
Strategic investment and exit opportunities
Pharma licensing & partnerships
High interest from immunology and oncology leaders.
Strong competitive positioning
No direct competitors in Treg activation.
Co-development & alliances
Potential for co-development and strategic alliances.
Acquisition or IPO
High-value acquisition or IPO potential.
Investor documents
The investor brief, on request
We share the full investment case in direct conversation, not as a public download. Request access and the brief is sent to you personally.
- ml@cd4therapeutics.com
- +49 160 2517541
- CD4 Therapeutics GmbH, Kiefernweg 38, 82319 Starnberg, Germany
Request access
Takes a minute. The brief is sent personally, usually within two business days.